A Study of Safety and Effectiveness of Intra Venous Iron Sucrose Therapy in Pregnant Women Suffering From Moderate to Severe Iron Deficiency Anaemia Disease

Aims & Objectives: To determine the effectiveness and safety of IV Iron sucrose therapy in antenatal women with moderate to severe Iron deficiency anaemia.

Methodology: It is a retrospective study with secondary data analysis. We have analyzed the data collected from January 2019 to December 2019 at the Nootan general hospital, Visnagar, Gujarat, India. Analysis of antenatal women with moderate to severe anaemia (Hb 6 to 8gm%) in the second trimester and early third trimester(20 to 34weeks of gestation) are done during their routine antenatal care who were prescribed Intravenous Iron sucrose in a standard-dose of 1000 mg given as 200 mg on alternate days after confirming the iron deficiency anaemia. Effectiveness of the therapy has been studied by comparing the Hb level at the point baseline where start of the treatment and 4 week or more after the last treatment was given (endline). The safety profile of the therapy has been assessed by noticing any adverse drug reaction after starting the infusion.

Results: Mean increase in Hb in cases of moderate & severe anaemia was 3.69 g/dl (1.19) and 3.91 (1.25) g/dl respectively. Overall rise of Haemoglobin was 3.79 g/dl (1.1)(95% CL: 3.35, 4.23). Calculated p value in our study is < 0.001 which is statistically significant.

Conclusion: The mean rise in Haemoglobin level in our study was 3.79 g/dL when 1000 mg of Intra venous iron sucrose was given to antenatal women with moderate as well as severe anaemia is concerned. The magnitude of the anaemia difference is directly proportional rise of haemoglobin level. The amount of haemoglobin rise is seen more in severe anaemic antenatal patients compared with moderate antenatal patients. We recommend that Intravenous iron sucrose therapy should be included as second choice for severely anaemic pregnant women where situation is not supportive for blood transfusion or patient is noncompliant.